<p>Bluejay Diagnostics (BJDX) 的股票在周二经历了极大的上涨，此前这家医疗诊断公司与 Argonaut Manufacturing Services 签署了一项协议。两家公司达成了战略合作伙伴关系，Argonaut Manufacturing Services 将支持 Bluejay Diagnostics 的 Symphony 平台的开发。Symphony 是一个用于脓毒症分诊和疾病进展监测的检测系统。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁可信赖的数据驱动投资工具，使用 TipRanks Premium，从分析师评级和预测到突发新闻和投资组合分析。</li>
<li>通过 TipRanks 智能投资者通讯发现高信念股票推荐和新的投资机会。</li>
</ul>
<p>Bluejay Diagnostics 指出，这项协议旨在扩大其在美国的制造能力。公司希望这将增强其未来的商业基础设施并提升供应链的韧性。这样做将有助于防止公司受到关税和国际贸易影响。这对 Bluejay Diagnostics 来说是一个重大变化，因为该公司在很大程度上依赖海外制造。</p>
<p>Bluejay Diagnostics 的总裁兼首席执行官 Neil Dey 对与 Argonaut Manufacturing Services 的战略合作伙伴关系表示满意。他表示，这 &#34;反映了我们在朝着关键商业里程碑迈进时，建立可扩展和以质量为中心的运营基础的承诺。&#34;</p>
<h2><strong>Bluejay Diagnostics 今日股票动态</strong></h2>
<p>Bluejay Diagnostics 的股票在周二的盘前交易中上涨了 184.33%，此前在周一上涨了 1.4%。然而，该股票年初至今下跌了 18.67%，过去 12 个月下跌了 69.52%。</p>
<p>今天 BJDX 股票的交易活动强劲，约有 3300 万股易手。相比之下，该公司的三个月平均日交易量约为 527 万股。</p>
<h2><strong>Bluejay Diagnostics 股票是买入、卖出还是持有？</strong></h2>
<p>转向华尔街，传统分析师对 Bluejay Diagnostics 股票的覆盖不足。幸运的是，TipRanks 的 AI 分析师 Spark 对此进行了覆盖。Spark 将 BJDX 股票评级为中性，目标价为 1.50 美元。它将 &#34;非常疲弱的财务表现（收入微薄、持续亏损和持续现金消耗）&#34; 作为这一立场的理由。</p>

BJDX

<p>Bluejay Diagnostics (BJDX) 的股票在盘前交易中上涨超过 184%，原因是与 Argonaut Manufacturing Services 签署了战略合作伙伴关系。该协议旨在扩大其 Symphony 败血症检测平台在美国的制造能力，增强供应链的韧性，并减少对海外生产的依赖。尽管股价上涨，BJDX 今年迄今为止和过去一年仍大幅下跌。TipRanks 的 AI 分析师 Spark 将该股票评级为中性，目标价为 1.50 美元，理由是财务表现疲弱</p>

<p>Bluejay Diagnostics (BJDX) stock underwent an extreme rally on Tuesday after the medical diagnostics company signed an agreement with Argonaut Manufacturing Services. The two companies have agreed to a strategic partnership that will see Argonaut Manufacturing Services support the development of Bluejay Diagnostics' Symphony platform. Symphony is a testing system for sepsis triage and monitoring of disease progression.</p>
<div class="lb-trans"><p>Bluejay Diagnostics (BJDX) 的股票在周二经历了极大的上涨，此前这家医疗诊断公司与 Argonaut Manufacturing Services 签署了一项协议。两家公司达成了战略合作伙伴关系，Argonaut Manufacturing Services 将支持 Bluejay Diagnostics 的 Symphony 平台的开发。Symphony 是一个用于脓毒症分诊和疾病进展监测的检测系统。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.</li>
<li>Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁可信赖的数据驱动投资工具，使用 TipRanks Premium，从分析师评级和预测到突发新闻和投资组合分析。</li>
<li>通过 TipRanks 智能投资者通讯发现高信念股票推荐和新的投资机会。</li>
</ul>
</div><p>Bluejay Diagnostics noted that this agreement is designed to expand its U.S. manufacturing capabilities. The company hopes that this will strengthen its future commercial infrastructure and enhance supply chain resilience. Doing so would help prevent the company from having to deal with the effects of tariffs and international trade. This would be a major change for Bluejay Diagnostics, which largely relies on overseas manufacturing.</p>
<div class="lb-trans"><p>Bluejay Diagnostics 指出，这项协议旨在扩大其在美国的制造能力。公司希望这将增强其未来的商业基础设施并提升供应链的韧性。这样做将有助于防止公司受到关税和国际贸易影响。这对 Bluejay Diagnostics 来说是一个重大变化，因为该公司在很大程度上依赖海外制造。</p>
</div><p>Neil Dey, president and CEO of Bluejay Diagnostics, was pleased with the strategic partnership with Argonaut Manufacturing Services. He said it &#34;reflects our commitment to building a scalable and quality-focused operational foundation as we progress toward key commercial milestones.&#34;</p>
<div class="lb-trans"><p>Bluejay Diagnostics 的总裁兼首席执行官 Neil Dey 对与 Argonaut Manufacturing Services 的战略合作伙伴关系表示满意。他表示，这 &#34;反映了我们在朝着关键商业里程碑迈进时，建立可扩展和以质量为中心的运营基础的承诺。&#34;</p>
</div><h2><strong>Bluejay Diagnostics Stock Movement Today</strong></h2>
<div class="lb-trans"><h2><strong>Bluejay Diagnostics 今日股票动态</strong></h2>
</div><p>Bluejay Diagnostics stock was up 184.33% in premarket trading on Tuesday, following a 1.4% rally yesterday. However, the stock has fallen 18.67% year-to-date and 69.52% over the past 12 months.</p>
<div class="lb-trans"><p>Bluejay Diagnostics 的股票在周二的盘前交易中上涨了 184.33%，此前在周一上涨了 1.4%。然而，该股票年初至今下跌了 18.67%，过去 12 个月下跌了 69.52%。</p>
</div><p>BJDX stock trading activity today was strong, as some 33 million shares changed hands. For comparison, the company's three-month average daily trading volume was about 5.27 million shares.</p>
<div class="lb-trans"><p>今天 BJDX 股票的交易活动强劲，约有 3300 万股易手。相比之下，该公司的三个月平均日交易量约为 527 万股。</p>
</div><h2><strong>Is Bluejay Diagnostics Stock a Buy, Sell, or Hold?</strong></h2>
<div class="lb-trans"><h2><strong>Bluejay Diagnostics 股票是买入、卖出还是持有？</strong></h2>
</div><p>Turning to Wall Street, traditional analyst coverage of Bluejay Diagnostics stock is lacking. Fortunately, TipRanks' AI analyst Spark has it covered. Spark rates BJDX stock as Neutral with a $1.50 price target. It cites &#34;very weak financial performance (minimal revenue, ongoing losses, and persistent cash burn)&#34; as reasons for this stance.</p>
<div class="lb-trans"><p>转向华尔街，传统分析师对 Bluejay Diagnostics 股票的覆盖不足。幸运的是，TipRanks 的 AI 分析师 Spark 对此进行了覆盖。Spark 将 BJDX 股票评级为中性，目标价为 1.50 美元。它将 &#34;非常疲弱的财务表现（收入微薄、持续亏损和持续现金消耗）&#34; 作为这一立场的理由。</p>
</div>

为什么便士股 Bluejay Diagnostics（BJDX）今天上涨？